查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2020210

肌萎缩侧索硬化症 (ALS) 治疗市场：规模、份额、成长和全球产业分析（按类型和应用）、区域洞察以及 2026-2034 年预测

Amyotrophic Lateral Sclerosis Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 100 Pages | 商品交期: 请询问到货日

价格

肌萎缩侧索硬化症 (ALS) 治疗市场的成长要素

全球肌萎缩侧索硬化症 (ALS) 治疗市场预计在 2025 年达到 8.9 亿美元，2026 年成长至 10.3 亿美元，最终在 2034 年达到 21.9 亿美元，在 2026 年至 2034 年的预测期内，复合年增长率将达到 9.93%。北美在 2025 年将以 54.37% 的市占率领先，这主要得益于已通过核准药物的商业化以及该地区对 ALS 的认识不断提高。

肌萎缩侧索硬化症（ALS），又称渐路格里克氏病，是一种进行性神经退化性疾病，会导致肌肉无力并损害身体机能。目前尚无根治性，但托福生、Edaravone和Riluzole等治疗方法可以帮助控制症状并延缓疾病进展。 ALS盛行率的上升以及ALS协会、I AM ALS、ACELA和荷兰ALS协会等组织开展的宣传活动，正在推动这些药物的市场需求。

新冠疫情期间，由于就诊量减少、供应链中断，ALS治疗市场出现萎缩。然而，从2021年到2022年，随着疾病负担加重，更多患者寻求有效治疗，市场开始復苏。

市场趋势

市场关键趋势之一是开髮用于治疗肌萎缩侧索硬化症（ALS）的新药。各公司正积极进行临床试验，力求将创新治疗方法推向市场。例如，AL-S Pharma于2021年启动了AP-101的II期临床试验，预计将于2025年1月完成。同样，Clene Nanomedicine也启动了CNMAu8的II期临床试验，预计将于2024年12月完成。对新治疗方法的关注预计将显着推动市场成长。

成长要素

全球肌萎缩侧索硬化症（ALS）治疗市场的需求成长主要受ALS患者日益沉重的负担以及各国政府支持研发的倡议所驱动。像Radica（Edaravone）这样获得美国FDA核准的药物需求量很大，因为它们可以延缓疾病的进展。 ALS的盛行率在全球呈上升趋势。例如，在义大利撒丁岛，ALS的盛行率从2015年的每10万人15.26例上升到2019年的每10万人18.31例。世界各国政府都在加大对ALS研究的投入，以拓展治疗方法选择；例如，加拿大透过加拿大卫生研究院（CIHR）在2023年投入了4000万美元。

抑制因子

肌萎缩侧索硬化症（ALS）药物的高昂费用和副作用限制了市场成长。例如，Radicava 等药物每年费用高达 17.1 万美元左右，并可能导致头晕、虚弱和呼吸困难。由于患者倾向于选择营养支持、语言治疗、物理治疗和手术等替代疗法，高昂的费用和副作用阻碍了 ALS 药物的普及。

市场区隔

依药物类型：

  • 由于依达拉奉获得了全球核准，并且有口服和注射两种给药途径，预计到 2026 年，Edaravone奉将引领市场，占据 57.88% 的市场份额。
  • 其他药物，包括正在研发中的药物，如 CNMAu8、MRG-001 和 AP-101，也显示出很高的成长潜力。

依管理途径：

  • 到 2026 年，口服药物预计将占据市场主导地位，市场份额达到 50.24%，这主要得益于 Relyvrio、Radicava 和 Rilutek 等口服製剂的推动。
  • 预计注射剂药物领域将以最高的复合年增长率成长，这得益于 QALSODY 的核准。

按分销管道：

  • 到 2026 年，医院药局将占据市场领先地位，市场占有率达到 54.29%，这得益于专业的员工队伍和病患的偏好。
  • 受孤儿药线上分销的推动，零售药局和网路药局的成长速度最快。

区域趋势

预计北美将在2025年以4.8亿美元的市场规模占据主导地位，并在2026年达到5.5亿美元，这主要得益于强效药物的商业化和核准。光是美国市场预计在2026年就将达到5.04亿美元。

2025 年欧洲市场将达到 2.4 亿美元，预计到 2026 年将成长至 2.7 亿美元，这得益于 QALSODY 和 Radicava 的商业化以及管道核准。

预计亚太地区市场规模将在2025年达到9,000万美元，2026年达到1.2亿美元。 PTC Therapeutics和Clene Nanomedicine公司不断提高的市场认知度和临床试验预计将推动该地区实现最高的复合年增长率。预计日本市场规模将在2025年达到3,160万美元，中国市场规模将在2026年达到2,800万美元，印度市场规模将在2026年达到900万美元。

世界其他地区由于人们对 ALS 的认识提高和患病率上升，预计将出现显着增长。

主要企业

主要市场参与者包括百健（Biogen）、田边三菱製药（Tanabe Mitsubishi Pharma）、赛诺菲（Sanofi）、EDW製药（EDW Pharma）、Aculicit Therapeutics、大冢製药（Otsuka Pharmaceutical）、诺华（Novartis）、Zydus Life Sciences、Crane Nanomedicine、Crane Nano。这些公司正专注于药物商业化、临床试验併购，以加强产品系列。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 肌萎缩侧索硬化症的流行病学—按主要国家和地区划分，2025 年
  • 管道分析：按主要企业划分
  • 主要产业趋势（合併、收购、合作等）
  • 新冠疫情对市场的影响

第五章：全球市场分析、洞察与预测（2021-2034年）

  • 市场分析、洞察与预测：按药物类型划分
    • 託费尔森
    • Edaravone
    • Riluzole
    • 其他的
  • 市场分析、洞察与预测：按给药途径
    • 口服
    • 肠外
  • 市场分析、洞察与预测：按分销管道划分
    • 医院药房
    • 实体店和网路药局
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 世界其他地区

第六章：北美市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 其他欧洲国家

第八章：亚太市场分析、洞察与预测（2021-2034年）

  • 国家
    • 日本
    • 中国
    • 澳洲
    • 印度
    • 其他亚太国家

第九章：2021-2034年世界其他地区市场分析、洞察与预测

第十章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Biogen
    • Mitsubishi Tanabe Pharma
    • Sanofi
    • EDW Pharma, Inc.
    • Aquestive Therapeutics
    • Otsuka Pharmaceutical, Inc.
    • Novartis Pharmaceuticals
    • Zydus Lifesciences Limited
    • Clene Nanomedicine
    • Annexon, Inc.
Product Code: FBI110139

Growth Factors of amyotrophic lateral sclerosis (ALS) therapeutics Market

The global amyotrophic lateral sclerosis (ALS) therapeutics market was valued at USD 0.89 billion in 2025 and is projected to grow to USD 1.03 billion in 2026, ultimately reaching USD 2.19 billion by 2034, registering a CAGR of 9.93% during the forecast period of 2026-2034. North America led the market in 2025 with a share of 54.37%, attributed to the commercialization of approved drugs and heightened awareness of ALS in the region.

ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that weakens muscles and impairs physical function. Although no cure exists, treatments such as tofersen, edaravone, and riluzole help manage symptoms and slow disease progression. The rising prevalence of ALS and increasing awareness driven by organizations like ALS Association, I AM ALS, ACELA, ALS Netherlands, and others have boosted market demand for therapeutics.

During the COVID-19 pandemic, the ALS therapeutics market experienced a decline due to reduced hospital visits for diagnosis and treatment, along with supply chain disruptions. However, market recovery occurred in 2021-2022 as the disease burden increased and more patients sought effective care.

Market Trends

One of the key trends in the market is the development of novel drugs for ALS treatment. Companies are actively engaging in clinical trials to bring innovative therapies to the market. For example, AL-S Pharma initiated phase 2 trials for AP-101 in 2021, expected to complete in January 2025, and Clene Nanomedicine started phase 2 trials for CNMAu8, completing in December 2024. The emphasis on new therapeutics is expected to significantly drive market growth.

Growth Factors

The global ALS therapeutics market is fueled by the growing burden of ALS and government initiatives supporting research and development. Drugs like Radicava (edaravone), approved by the U.S. FDA, slow disease progression, increasing demand. The prevalence of ALS has been rising worldwide; for instance, in Sardinia, Italy, ALS prevalence increased from 15.26 per 100,000 in 2015 to 18.31 per 100,000 in 2019. Governments are investing in research, such as Canada's USD 40 million funding via CIHR in 2023, to advance therapeutic options.

Restraining Factors

High costs and side effects associated with ALS drugs limit market growth. Treatments like Radicava can cost approximately USD 171,000 per year and may cause dizziness, weakness, and breathing issues. The high cost and adverse effects often push patients toward alternative therapies, including nutritional support, speech therapy, physical therapy, and surgery, restraining the adoption of ALS therapeutics.

Market Segmentation

By Drug Type:

  • Edaravone is projected to dominate with 57.88% share in 2026, driven by global approvals and oral/parenteral availability.
  • Others, including pipeline drugs like CNMAu8, MRG-001, and AP-101, also show strong growth potential.

By Route of Administration:

  • Oral drugs dominated in 2026 with 50.24% share, driven by Relyvrio and other oral formulations like Radicava and Rilutek.
  • The parenteral segment is expected to grow at the fastest CAGR, aided by QALSODY's approval.

By Distribution Channel:

  • Hospital pharmacies led with 54.29% share in 2026, supported by trained staff and patient preference.
  • Retail and online pharmacies are growing fastest, facilitated by orphan drug distribution online.

Regional Insights

North America dominated in 2025 with USD 0.48 billion, projected to reach USD 0.55 billion in 2026 due to strong drug commercialization and approvals. The U.S. market alone is forecast to reach USD 0.504 billion in 2026.

Europe contributed USD 0.24 billion in 2025, expected to grow to USD 0.27 billion in 2026, supported by QALSODY and Radicava commercialization and pipeline approvals.

Asia Pacific had USD 0.09 billion in 2025, projected to reach USD 0.12 billion in 2026, experiencing the fastest CAGR due to rising awareness and clinical trials by PTC Therapeutics and Clene Nanomedicine. Japan is expected at USD 31.6 million in 2025, China at USD 0.028 billion in 2026, and India at USD 0.009 billion in 2026.

The rest of the world is anticipated to grow substantially due to increased awareness and ALS prevalence.

Key Players

Prominent market players include Biogen, Mitsubishi Tanabe Pharma, Sanofi, EDW Pharma, Aquestive Therapeutics, Otsuka Pharmaceutical, Novartis, Zydus Lifesciences, Clene Nanomedicine, and Annexon. These companies focus on drug commercialization, clinical trials, and mergers & acquisitions to enhance their product portfolios.

Recent Developments:

  • May 2024: Biogen received European approval for QALSODY.
  • May 2022: Mitsubishi Tanabe Pharma gained U.S. FDA approval for Radicava.
  • May 2022: Sanofi initiated Phase 2 HIMALAYA Study for SAR443820.
  • March 2022: Aquestive Therapeutics licensed Riluzole oral film in China.

Conclusion

The global amyotrophic lateral sclerosis therapeutics market is projected to exhibit strong growth from USD 0.89 billion in 2025 to USD 2.19 billion by 2034 at a CAGR of 9.93%, driven by rising ALS prevalence, novel drug development, and supportive government initiatives. However, high treatment costs and side effects may restrain adoption, while oral drug formulations and hospital pharmacy distribution dominate market segments. North America remains the largest market, with Asia Pacific demonstrating the fastest growth potential.

Segmentation By Drug Type

  • Tofersen
  • Edaravone
  • Riluzole
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacy
  • Retail & Online Pharmacy

By Region

  • North America (by Drug Type, by Route of Administration, by Distribution Channel, and by Country)
    • U.S.
    • Canada
  • Europe (by Drug Type, by Route of Administration, by Distribution Channel, and by Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (by Drug Type, by Route of Administration, by Distribution Channel, and by Country/Sub-region)
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia Pacific
  • Rest of the World (by Drug Type, by Route of Administration, and by Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Amyotrophic Lateral Sclerosis - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis - by Key Companies
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.4. Impact of COVID-19 on the Market

5. Global Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Type
    • 5.1.1. Tofersen
    • 5.1.2. Edaravone
    • 5.1.3. Riluzole
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Retail & Online Pharmacy
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Type
    • 6.1.1. Tofersen
    • 6.1.2. Edaravone
    • 6.1.3. Riluzole
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacy
    • 6.3.2. Retail & Online Pharmacy
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Type
    • 7.1.1. Tofersen
    • 7.1.2. Edaravone
    • 7.1.3. Riluzole
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail & Online Pharmacy
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Type
    • 8.1.1. Tofersen
    • 8.1.2. Edaravone
    • 8.1.3. Riluzole
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail & Online Pharmacy
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. Australia
    • 8.4.4. India
    • 8.4.5. Rest of Asia Pacific

9. Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Type
    • 9.1.1. Tofersen
    • 9.1.2. Edaravone
    • 9.1.3. Riluzole
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail & Online Pharmacy

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Biogen
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Mitsubishi Tanabe Pharma
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Sanofi
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. EDW Pharma, Inc.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Aquestive Therapeutics
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Otsuka Pharmaceutical, Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Novartis Pharmaceuticals
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Zydus Lifesciences Limited
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Clene Nanomedicine
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)
    • 10.2.10. Annexon, Inc.
      • 10.2.10.1. Overview
      • 10.2.10.2. Products & services
      • 10.2.10.3. SWOT Analysis
      • 10.2.10.4. Recent Developments
      • 10.2.10.5. Strategies
      • 10.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 2: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 6: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 10: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 14: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 18: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034a

List of Figures

  • Figure 1: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2021 & 2034
  • Figure 2: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2021 & 2034
  • Figure 3: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2021 & 2034
  • Figure 4: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2021 & 2034
  • Figure 5: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Region, 2021 & 2034
  • Figure 6: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
  • Figure 7: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 8: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
  • Figure 9: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
  • Figure 11: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), By Country, 2021 & 2034
  • Figure 13: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), By Country, 2025
  • Figure 14: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
  • Figure 15: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 16: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
  • Figure 17: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
  • Figure 19: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), By Country/ Sub-region, 2021 & 2034
  • Figure 21: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
  • Figure 23: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 24: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
  • Figure 25: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
  • Figure 27: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), By Country/ Sub-region, 2021 & 2034
  • Figure 29: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
  • Figure 31: Latin America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 32: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
  • Figure 33: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
  • Figure 35: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Global Amyotrophic Lateral Sclerosis Therapeutics Market Share (%), By Company, 2025